FDA's Rejection of MDMA Therapy: Implications and Advocacy

This chapter explores the recent FDA decision to reject MDMA-assisted therapy for PTSD, raising critical questions about the motivations and influences impacting the approval process. It features insights from stakeholders in the psychedelic research community, highlighting the urgent need for effective mental health treatments, especially for veterans. The conversation emphasizes ongoing advocacy efforts for psychedelic therapy and the potential dangers of setting high approval standards that could hinder future access to beneficial treatments.